CMML

Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China

Retrieved on: 
Monday, October 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LinkedIn, ILT4, Immunoglobulin G, HLA-G, Pembrolizumab, Therapy, ILT3, Acute myeloid leukemia, CD1D, White blood cell, AML, Tislelizumab, LILRB4, LAIR1, Azacitidine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Drug development, California Institute for Regenerative Medicine, Lymphatic system, CIRM, Research, NIH, Twitter, Â, Immunotherapy, Orphan drug, Cancer, Apolipoprotein E, Food, Tumor microenvironment, Leukemia, National Cancer Institute, SEMA4A, Leukemia & Lymphoma Society, American Association, National, Association, PD-1, LLS, Adult, Chronic myelomonocytic leukemia, CMML, Record, LILRB2, Regenerative medicine, NCI, Vaccine, Pharmaceutical industry, BeiGene

By expanding our reach with BeiGene in China, we have an opportunity to treat a broader array of patients with significant unmet medical needs.

Key Points: 
  • By expanding our reach with BeiGene in China, we have an opportunity to treat a broader array of patients with significant unmet medical needs.
  • Based on strong preclinical and emerging clinical data, we believe there is good synergy between PD-1 and LILRB antagonists for the treatment of solid tumors.
  • Under the terms of the collaboration, Immune-Onc will sponsor and fund the IO-108 and IO-202 clinical trials in China, and BeiGene will provide tislelizumab.
  • The company is actively enrolling a Phase 1 clinical trial in China to evaluate IO-108 in solid tumors.

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Retrieved on: 
Monday, October 3, 2022
Chronic myelomonocytic leukemia, Association, Translational research, CLL, Lymphoma, TET2, RHOA, JCA, Research, Myelodysplastic syndrome, Disease, Lymphatic system, SF, AML, Infection, Chronic lymphocytic leukemia, Japanese Cancer Association, CHF, Acute myeloid leukemia, Medicine, Oncogene, Dasatinib, Safety, RNA, Patient, General Medicine Faculty of RostGMU (Rostov State Medical University), IDH, Isocitrate dehydrogenase, MDS, University, CMML, Pharmaceutical industry, Debiopharm

LAUSANNE, Switzerland , Oct. 3, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational Research – Prof. Mamiko Sakata-Yanagimoto. The winners were honored with trophies and a monetary prize during the live event of the 81st Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 1st in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Thierry Mauvernay, President of Debiopharm, and Bertrand Ducrey CEO of Debiopharm. 

Key Points: 
  • "The previous winners of the Mauvernay Award have immediately becomevery well-known scientists in our country, becoming professors and leaders in significant institutes.
  • Therefore, I would say that the Mauvernay Award is definitely a huge step for young cancer research scientists in our country."
  • Dr. Akihide Yoshimi's disruptive research at the National Cancer Center Research Institute, is aimed at understanding and targeting aberrant RNA splicing inhematological malignancies.
  • Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.

Humanigen Reports Second Quarter 2022 Financial Results

Retrieved on: 
Friday, August 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Chronic myelomonocytic leukemia, Survival, Granulocyte-macrophage colony-stimulating factor, Mortality, Hercules, Rating, ATM, Research, Patient, Term loan, COVID-19, Haematopoietic system, Research and development, GM-CSF, National, Lymphatic system, Nasdaq, Pharmaceutical industry, Tutoring, Cryptocurrency, CMML

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.
  • Second Quarter and Six Months Ended June 30, 2022 Financial Results
    Net loss for the quarter ended June 30, 2022 was $30.1 million, or $0.43 per share, as compared to $70.8 million, or $1.20 per share, for the quarter ended June 30, 2021.
  • The decrease in R&D expense is primarily due to decreased lenzilumab manufacturing costs for the quarter ended June 30, 2022 of $34.6 million, and for the six months ended June 30, 2022 of $70.3 million.
  • Subsequent to end of the quarter and through August 10, 2022, the company raised an additional $15.9 million under the ATM.

Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom

Retrieved on: 
Thursday, June 16, 2022
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, SHIELD, CMML, COVID-19, Risk, Safety, National Health Service, Health care, MHRA, GM, Conditional, ClinicoEconomics and Outcomes Research, Lenzilumab, Knowledge, Graft-versus-host disease, CDMO, Forward-looking statement, Non-Hodgkin lymphoma, Medication, LinkedIn, RAS, PCI, Rheumatoid arthritis, Clinical trial, GM-CSF, Chemokine, UK Health Security Agency, SEC, National Health Service (England), Nasdaq, Neurotoxicity, Granulocyte-macrophage colony-stimulating factor, Twitter, Standard of care, Chronic myelomonocytic leukemia, Patient, Cytokine release syndrome, Gilead Sciences, Degenerative disease, Outcomes research, Goal, Judgement, Pharmaceutical industry, Hospital, Vaccine, Animal, Facebook

Hospitalizations from COVID-19 continue in the United Kingdom with more than 235,000 admitted year-to-date and with ~5,000 currently hospitalized.1 In addition, Humanigen believes that treatment with lenzilumab may deliver economic value to the healthcare system.

Key Points: 
  • Hospitalizations from COVID-19 continue in the United Kingdom with more than 235,000 admitted year-to-date and with ~5,000 currently hospitalized.1 In addition, Humanigen believes that treatment with lenzilumab may deliver economic value to the healthcare system.
  • Lenzilumab binds to and neutralizes GM-CSF, potentially improving outcomes for patients hospitalized with COVID-19.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
  • https://doi.org/10.2147/CEOR.S360741
    Humaneered is a trademark of Humanigen, Inc.
    Yescarta and Tecartus are trademarks of Gilead Sciences, Inc., or its related companies.

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Retrieved on: 
Friday, June 10, 2022
ASM, Congress, Part Two, Intracranial hemorrhage, Anemia, The Twilight Saga: Breaking Dawn – Part 1, LinkedIn, Annual report, Forward-looking statement, Mastocytosis, Webcast, HER2/neu, Disease, KIT, AML, Nasdaq, Dana–Farber Cancer Institute, FGFR2, Physician, CMML, Risk, Neutropenia, PEAK, Patient, MCL, GLOBE, Division, Acute myeloid leukemia, BID, Private Securities Litigation Reform Act, Mast cell leukemia, Chronic myelomonocytic leukemia, EHA, Peripheral edema, SEC, Twitter, Social media, Clinical trial, B cell, GIST, Thrombocytopenia, APEX, CNS, Mutation, Safety, Pharmaceutical industry, Risk management, Leukemia, Cogent

CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The data are being presented today in a poster presentation at the 2022 European Hematology Association (EHA) Congress in Vienna, Austria.

Key Points: 
  • and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).
  • APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial in patients with AdvSM evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
  • Patients were enrolled with the following sub-types: two patients with aggressive systemic mastocytosis (ASM), eight patients with systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and one patient with mast cell leukemia (MCL).
  • As of the data cutoff date ofMay 24, 2022, all 11 patients treated were evaluated for signs of clinical activity.

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

Retrieved on: 
Wednesday, April 20, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, LILRB2, Drug development, Immunotherapy, CIRM, Biotechnology, California Institute for Regenerative Medicine, Investigational New Drug, Lymphocyte, NIH, IND, National Cancer Institute, Leukemia, LILRB4, Leukemia & Lymphoma Society, Twitter, Memorial Sloan Kettering Cancer Center, University, LLS, Research, CMML, PD-1, Food, Science, SITC, CA, Chronic myelomonocytic leukemia, White blood cell, ILT4, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LAIR1, National, Patient, LinkedIn, Myelocyte, University of Texas at Austin, Company, Albert Einstein College of Medicine, ILT3, Society, Lymphatic system, AML, Regenerative medicine, Society for Immunotherapy of Cancer, Tumor microenvironment, Biology, Antibody, Collagen, NCI, Cancer, Record, Acute myeloid leukemia, Therapy, Survival, Vaccine

Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the selection of IO-106, a first-in-class myeloid and stromal checkpoint inhibitor targeting the inhibitory receptor, LeukocyteAssociated ImmunoglobulinLike Receptor 1 (LAIR1), for clinical development.

Key Points: 
  • Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the selection of IO-106, a first-in-class myeloid and stromal checkpoint inhibitor targeting the inhibitory receptor, LeukocyteAssociated ImmunoglobulinLike Receptor 1 (LAIR1), for clinical development.
  • LAIR1 is an immune inhibitory receptor expressed on lymphocytes and myeloid cells that correlates with worse survival in several cancers.
  • We are very excited about potential development opportunities for IO-106 and look forward to sharing our progress in the near future.
  • Immune-Onc Therapeutics, Inc. (Immune-Onc) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.

GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia

Retrieved on: 
Wednesday, April 20, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SHIELD, Granulocyte-macrophage colony-stimulating factor, Cytokine release syndrome, GM-CSF, Adoption, Judgement, Lenzilumab, COVID-19, MBA, Twitter, Graft-versus-host disease, Gilead Sciences, Research, NHL, CMML, Toxicity, Chronic myelomonocytic leukemia, Risk, Patient, Goal, GM, Degenerative disease, Toxic shock syndrome, LinkedIn, Blood, Neurotoxicity, Mayo Clinic Cancer Center, Rheumatoid arthritis, Nasdaq, Apoptosis, RAS, SEC, Forward-looking statement, Chemokine, Safety, DLBCL, Disease, Physician, Non-Hodgkin lymphoma, CRS, Knowledge, Neuroinflammation, Synthetic biology, Vaccine, Pharmaceutical industry, Leukemia, Morris, Facebook

Treatments that can prevent ICANS and CRS while potentially improving CAR-T efficacy could address a critical unmet need.

Key Points: 
  • Treatments that can prevent ICANS and CRS while potentially improving CAR-T efficacy could address a critical unmet need.
  • The upcoming Phase 3 CAR-T study, known as SHIELD, will determine the efficacy and safety of prophylactic lenzilumab on the rates of ICANS, CRS, and CAR-T efficacy.
  • The SHIELD trial has been designed to build on the positive results from the ZUMA-19 study.
  • A study of lenzilumab is also underway for patients with chronic myelomonocytic leukemia (CMML) exhibiting RAS pathway mutations.

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

Retrieved on: 
Tuesday, April 19, 2022
Pharmaceutical, Genetics, Health, Oncology, LILRB2, Drug development, Physiology, CIRM, Biotechnology, California Institute for Quantitative Biosciences, Raymond James Financial, NIH, National Cancer Institute, Leukemia, LILRB4, Leukemia & Lymphoma Society, Twitter, Memorial Sloan Kettering Cancer Center, University, LLS, Research, CMML, Immunotherapy, Food, White blood cell, ILT4, Chronic myelomonocytic leukemia, Regulation of tobacco by the U.S. Food and Drug Administration, LAIR1, National, Patient, LinkedIn, University of Texas at Austin, Company, Albert Einstein College of Medicine, ILT3, Lymphatic system, AML, Regenerative medicine, Tumor microenvironment, Biology, NCI, Record, University of Texas Southwestern Medical Center, Acute myeloid leukemia, California Institute for Regenerative Medicine, Therapy, Vaccine, Cancer

Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts.

Key Points: 
  • Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts.
  • As a private company and a leader in LILRB/ILT family of myeloid checkpoint target validation and therapeutics development, we are pleased to be invited to the Raymond James LILRB/ILT Symposium, said Charlene Liao, Ph.D., chief executive officer of Immune-Onc.
  • Immune-Onc was founded on groundbreaking science that first illuminated the role of the previously unexplored LILRB family of myeloid checkpoints in cancer.
  • Immune-Onc Therapeutics, Inc. (Immune-Onc) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.

Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022

Retrieved on: 
Saturday, April 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Therapy, PARP, AML, Forward-looking statement, IND, Bone marrow, Cytarabine, AACR, Program, Poly (ADP-ribose) polymerase, American Association, CEO, DHODH, MDS, Association, American Association for Cancer Research, Safety, CMML, Annual general meeting, Inflammation, Medication, Azacitidine, PI3K, Maintenance, Business, Founder CEO, Patient, Pharmaceutical industry

Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Key Points: 
  • Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
  • Rhizens poster presentations describe the preclinical characterization and differentiated features of its novel PARP inhibitor (RP12146) and preclinical data supporting the broad positioning of its DHODH inhibitor (RP7214) in AML.
  • Rhizen had earlier indicated that its PARP program had demonstrated differentiated IND enabling preclinical safety.
  • The additional preclinical data being presented at AACR 2022 suggests that this differentiated safety may be due to the lower bone marrow distribution of RP12146 and concomitantly lower haematological toxicity.

China Lobaplatin Research Markets Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Oncology, Research report, Apoptosis, Incidence, The Different Company, China Energy Research Report, ASAT, Pollution, Acute leukemia, Dosage form, CMML, NMPA, DNA, Cell proliferation, Breast cancer, Chronic myelomonocytic leukemia, COVID-19, CAGR, Nedaplatin, Cisplatin, Squamous cell carcinoma, Animal, Motor vehicle

The "Research Report on China's Lobaplatin Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Lobaplatin Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's market research, there are five types of platinum-based antitumor drugs commonly used in China: first-generation cisplatin, second-generation carboplatin and nedaplatin, third-generation oxaliplatin and lobaplatin.
  • According to the publisher's market research, since its launch in China, lobaplatin showed an upward trend in sales volume and value from 2005 to 2019.
  • Prospects of China's Lobaplatin Market, 2021-2025
    2 Sales of Lobaplatin in China, 2016-2020
    2.3 Sales of Lobaplatin in China by Dosage Form, 2016-2020
    3 Analysis of Major Lobaplatin Manufacturers in China, 2020
    3.2 Hainan Changan International Pharmaceutical Co. Ltd
    4 Sales Price of Lobaplatin of Different Companies in China, 2020-2021
    4.1 Hainan Changan International Pharmaceutical Co.
    5 Prospects of China's Lobaplatin Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005712/en/